University of Illinois at Chicago
Announcement of an Exempt Purchase
Saptalis Pharmaceuticals, LLCHauppauge, NY
- Amount: An estimated $500,000
- Terms: An estimated start date of 9/27/2022 through 12/31/2025
- Renewals: None
0 BEP vendors
0 VBP vendors
0 Small businesses
The University award process may be delayed up to thirty days as this award goes through a state approval process.
First published Wednesday, October 5, 2022
The University awarded a contract for development of OSIG eye drop formulation.
Development of OSIG eye drop formulation using Quality by Design (QbD) principles. Detailed Target Profile Development using certificate of analysis (CoAs) and identifying compatible excipients (Consulting and Formulation Development Services for R24 Project: Immunotherapy for Ocular Surface Diseases).
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for performing sponsored research and other sponsored activities under grants and contracts funded by the sponsor or by sources other than State appropriations. (30 ILCS 500 / 1-13(b)(8)) Saptalis is a specialty pharmaceutical company with emphasis on developing complex generics, difficult to formulate dosage forms, and novel drug delivery systems. Additionally, this vendor has been approved by the awarding agency (National Eye Institute) to conduct research and development for the principle investigator at UIC using grant funding.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire
qualified veterans, minorities, females, persons with disabilities and ex-offenders.